Palisade Capital Management’s Travere Therapeutics TVTX Stock Holding History

Palisade Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-11,502	Closed	-$163K	–	444
2019 Q4	$163K	Sell	11,502 -2,000	-15%	-$25.5K	﹤0.01%	406
2019 Q3	$156K	Buy	13,502 +2,000	+17%	+$33.1K	﹤0.01%	414
2019 Q2	$231K	Buy	11,502 +1,000	+10%	+$19.7K	0.01%	395
2019 Q1	$238K	Sell	10,502 -250	-2%	-$5.53K	0.01%	413
2018 Q4	$243K	Buy	10,752 +2,252	+26%	+$56K	0.01%	419
2018 Q3	$244K	Buy	+8,500	New	+$243K	0.01%	440

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Palisade Capital Management's TVTX Position: Q1 2020 in Review

Palisade Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2020, closing a stake of 11,502 shares — an estimated $163K sold.

Palisade Capital Management first reported a position in TVTX in Q3 2018 and held it in 6 quarters. The position peaked at $244K in Q3 2018. 124 funds tracked by Wall St. Rank hold TVTX as of Q1 2020.

Palisade Capital Management reported no remaining Travere Therapeutics position as of Q1 2020 after selling out during the quarter.
Palisade Capital Management sold 11,502 Travere Therapeutics shares in Q1 2020, an estimated $163K.
Palisade Capital Management first reported a position in Travere Therapeutics in Q3 2018 and held it in 6 quarters.
Palisade Capital Management's Travere Therapeutics position peaked at $244K in Q3 2018.
124 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2020.

Based on Palisade Capital Management's 13F filing for Q1 2020, filed 13 May 2020.